CycloSPORINE Injectable Product

Phase 1

CycloSPORINE Injectable Product is one of 34 therapeutic programs targeting Alopecia Areata. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alopecia AreataActive, not recruiting

Alopecia AreataPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Alopecia Areata

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

3 2

Otezla

Amgen

Approved

2 3

Kenalog

BBausch Health Americas, Inc.

Approved

11 4

Zolymbus

AbbVie

Approved

1 5

Daliresp

AstraZeneca

Approved

1 6

Xeljanz

PPrism Pharmaceuticals

Approved

8 7

Anzupgo

Jazz Pharmaceuticals

Approved

—8

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 9

Zocor

OOrganon and Co

Approved

1 10

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alopecia Areata1 trial

Pilot Study on Intralesional Cyclosporine for Alopecia Areata

Active, not recruiting·UUniversity of California, Davis·Phase 1·NCT07029204·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CycloSPORINE Injectable Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CycloSPORINE Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of California, Davis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of California, Davis

CycloSPORINE Injectable Product

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Alopecia Areata1 trial

References

Drug Info

Quick Facts

Related News